| Ticker | Company | Sector | SS | 1Y Return | Price Target | Consensus | Analysts | HF Score | P/E |
|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | Pharma | 10 | +20.8% | $255.22 | Strong Buy | 16B/4H/0S | 1.00 | ~18× |
| GOOGL | Alphabet | Technology | 10 | +121.3% | $427.50 | Strong Buy | 27B/5H/0S | 0.66 | 28.7× |
| AVGO | Broadcom | Semis | 10 | +84.6% | $480.04 | Strong Buy | 26B/4H/0S | 0.62 | 84.8× G |
| LLY | Eli Lilly | Pharma | 10 | +52.9% | $1,265.10 | Strong Buy | 20B/2H/1S | 0.65 | 39.1× |
| ASML | ASML Holding | Semis Equip | 10 | +115.9% | $1,791.40 | Strong Buy | 6B/0H/0S | 0.43 | 53.3× |
| DY | Dycom | Telecom Infra | 10 | +121.8% | $613.50+↑ | Strong Buy | 10B/0H/0S | 0.54 | ~30×* |
| ARGX | argenx SE | Biotech | 9 | +45.8% | $1,045.09 | Strong Buy | 16B/1H/0S | 0.51 | 45.4× |
| DVN | Devon+Coterra (merged) | E&P / Energy | 9 | +47.0% | $62.75 | Strong Buy | 17B/3H/0S | 0.996 | 12.2× |
| MDB | MongoDB | Cloud DB | 9 | +77.7% | $397.65 | Strong Buy | 23B/4H/0S | 0.22 | N/A |
| GH | Guardant Health | Precision Oncology | 9 | +219.3% | $131.73 (Our PT: $160) | Strong Buy | 15B/1H/0S | 0.08 | N/A |
| HQY | HealthEquity | HSA Benefits | 8 | -12.5% | $121.50 | Strong Buy | 10B/0H/1S | 0.44 | 32.2× |
| SBGSY | Schneider Electric | Industrials / Electrification | 9 | +26.7% | N/A | Buy | 26B/4H/0S | 0.50 | 36.5× |
| MRVL | Marvell Tech | AI Semis | 8 | +240.6% | $234.33 | Strong Buy | 26B/4H/0S | 0.11 | 71.6× G |
| JPM | JPMorgan Chase | Financial / Banking | 6 | +37.0% | $335.00 | Buy | 9B/8H/0S | 0.90 | 14.2× |
| PH | Parker Hannifin | Aerospace & Defense | 10 | +52.5% | $1,000 | Strong Buy | 14B/3H/0S | 0.75 | ~33× |
| STLD | Steel Dynamics | Steel / Materials | 10 | +116.7% | $275 | Buy | 14B/4H/0S | 0.45 | ~25× fwd |
| WWD | Woodward Inc. | Industrials / A&D | 8 | +64.3% | $420 | Strong Buy | 8B/1H/0S | 0.04 | ~49× fwd |
| MOG.A | Moog Inc. Cl A | Defense Actuation | 7 | +110.5% | $370 (Int. / Cons: $350) | Buy | 1B/0H/0S | N/A | ~42× fwd |
| ALNT | Allient Inc. | Precision Motion | 10 | +160.4% | $85 (Int. / Cons: $73.80) | Strong Buy | 4B/1H/0S | 0.68 | ~40× fwd |
| ROR.L | Rotork plc (LSE/GBp) | Flow Control / Infra | N/A | +37.1% | 390p | Buy | 11B/6H/0S | N/A | ~21× |
| ELF | e.l.f. Beauty | Consumer Defensive | 5 | −53.0% | $74.93 | Strong Buy | 12B/4H/0S | 0.89 | 57.9× GAAP |
| Ticker | Company | Total | Buy | Hold | Sell | Buy Rate | Consensus Bar | Avg PT | PT Upside | Best Analyst |
|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | 20 | 16 | 4 | 0 | 80% | $255.22 | ~+15% | Strong Buy | |
| GOOGL | Alphabet | 32 | 27 | 5 | 0 | 84% | $427.50 | ~+18% | Strong Buy | |
| AVGO | Broadcom | 30 | 26 | 4 | 0 | 87% | $480.04 | ~+32% | Strong Buy | |
| LLY | Eli Lilly | 23 | 20 | 2 | 1 | 87% | $1,265.10 | ~+28% | Strong Buy | |
| ASML | ASML Holding | 6 | 6 | 0 | 0 | 100% | $1,791.40 | ~+22% | Strong Buy | |
| DY | Dycom | 10 | 10 | 0 | 0 | 100% | $613.50 | ~+35% | Strong Buy | |
| ARGX | argenx | 17 | 16 | 1 | 0 | 94% | $1,045.09 | ~+18% | Strong Buy | |
| DVN | Devon Energy | 20 | 17 | 3 | 0 | 85% | $62.75 | ~+55% | Strong Buy | |
| MDB | MongoDB | 27 | 23 | 4 | 0 | 85% | $397.65 | ~+40% | Strong Buy | |
| GH | Guardant Health | 16 | 15 | 1 | 0 | 94% | $131.73 (Our: $160) | +1.6% | Strong Buy | |
| HQY | HealthEquity | 11 | 10 | 0 | 1 | 91% | $121.50 | ~+40% | Strong Buy | |
| SBGSY | Schneider Electric | 8 | 8 | 0 | 0 | 100% | N/A | N/A | Buy | |
| MRVL | Marvell Tech | 30 | 26 | 4 | 0 | 87% | $234.33 | ~+166% | Strong Buy | |
| JPM | JPMorgan Chase | 17 | 9 | 8 | 0 | 53% | $334.54 | ~+12% | Buy | |
| PH | Parker Hannifin | 17 | 14 | 3 | 0 | 82% | $1,000 | ~+4% | Strong Buy | |
| STLD | Steel Dynamics | 18 | 14 | 4 | 0 | 78% | $275 | ~+6% | Buy | |
| WWD | Woodward Inc. | 9 | 8 | 1 | 0 | 89% | $420 | ~+20% | Strong Buy | |
| MOG.A | Moog Inc. Cl A | 1 | 1 | 0 | 0 | 100% | $350 (Int: $370) | -2.8%* | Buy | |
| ALNT | Allient Inc. | 5 | 4 | 1 | 0 | 80% | $73.80 (Int: $85) | -7%* | Strong Buy | |
| ROR.L | Rotork plc (LSE) | 17 | 11 | 6 | 0 | 65% | 395p | ~+18% | Buy | |
| ELF | e.l.f. Beauty | 16 | 12 | 4 | 0 | 75% | $74.93 | ~+43% | Strong Buy |
ASML and DY are the only two stocks with a perfect 100% analyst Buy rating. ASML's EUV monopoly makes it a must-own. DY has unanimous bullishness on the BEAD/fiber buildout tailwind.
GOOGL (32), AVGO (30), MRVL (30), and MDB (27) have the deepest coverage — mega-cap and high-growth technology companies attract the most sell-side attention.
GH is near its consensus PT after a +219% 1Y run, though our proprietary PT of $160 implies ~23% upside. DVN (~$36) shows ~74% upside to the $62.75 PT as the combined entity trades at a significant discount to NAV.
HQY is the only stock with a negative 1-year return (-12.5%) despite a 91% Buy rate — the classic contrarian setup. PT of $121.50 implies ~40% upside.
| Ticker | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | CAGR (4Y) | Trend |
|---|---|---|---|---|---|---|---|
| ABBV | $56,197M | $58,054M | $14,076M* | $55,300M | $58,658M | +1.1% | Stable (Humira cliff navigated) |
| GOOGL | $257,637M | $282,836M | $307,394M | $350,018M | ~$390,000M | +11.0% | Accelerating (Cloud + AI) |
| AVGO | $27,450M | $33,203M | $35,819M | $51,574M | ~$60,000M | +21.7% | Accelerating (VMware + AI) |
| LLY | $28,318M | $28,541M | $34,124M | $45,042M | ~$58,000M | +19.6% | Accelerating (GLP-1 ramp) |
| ASML | €15,978M | €21,173M | €27,559M | €28,261M | ~€30,000M | +17.1% | Strong (EUV cycle) |
| DY | $3,323M | $3,654M | $4,487M | $5,094M | ~$6,200M | +17.0% | Accelerating (BEAD/fiber) |
| ARGX | €196M | €627M | €1,430M | €2,956M | €4,154M | +115.5% | Hypergrowth (VYVGART ramp) |
| DVN | $12,213M | $19,189M | $14,919M | $14,626M | ~$12,800M | +1.2% | Cyclical (oil price driven) |
| MDB | $590M | $874M | $1,284M | $1,682M | $2,009M | +35.9% | Strong (Atlas growth) |
| GH | $374M | $450M | $564M | $739M | $982M | +27.3% | Accelerating (Shield FDA) |
| HQY | $632M | $788M | $895M | $1,086M | ~$1,250M | +18.6% | Steady (HSA growth) |
| SBGSY | €28,900M | €34,200M | €35,900M | €38,200M | €40,200M | +8.6% | Steady compounder |
| MRVL | $2,972M | $5,518M | $5,921M | $5,510M | $8,225M | +29.1% | Accelerating (AI ASIC) |
| JPM | $127,700M | $158,300M | $177,000M | $173,000M | ~$183,000M | +5.8% | Steady (NII + CIB fees) |
| PH | $14,348M | $15,107M | $19,956M | $19,621M | ~$19,850M | +8.5% | ↑ Steady (Meggitt acquisition FY2023) |
| STLD | ~$13,200M | $22,260M | $19,390M | $17,220M | $18,180M | +8.3% | Cyclical — steel prices peaked FY2022 |
| WWD | $2,463M | $2,850M | $3,100M | $3,350M | $3,570M | +9.7% | ↑ Steady (A&D aftermarket ramp) |
| MOG.A | $2,571M | $2,930M | $3,200M | $3,550M | $3,860M | +10.7% | ↑ Steady (94% sole-source defense) |
| ALNT | $305M | $370M | $430M | $500M | $554M | +16.2% | ↑ Strong acquisitive growth (all $M) |
| ROR.L | £542M | £665M | £726M | £755M | £777M | +9.4% | ↑ Steady flow control compounder (£M) |
| ELF | $392M | $579M | $1,024M | $1,314M | $1,636M | +4.2× (4Y CAGR +43%) | Mass beauty + Naturium acq. FY24; rhode acq. FY26 |
| Ticker | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Direction | Commentary |
|---|---|---|---|---|---|---|---|
| ABBV | ~18% | ~19% | ~22% | ~23% | ~24% | ↑ Improving | Humira biosimilar erosion offset by Skyrizi/Rinvoq ramp |
| GOOGL | ~29% | ~21% | ~24% | ~26% | ~32.8% | ↑ Improving | Cost cuts + AI-driven monetization; record margins |
| AVGO | ~22% | ~24% | ~26% | ~11% | ~36.2% | ↑ Strong | FY2024 dip from VMware acquisition; recovered strongly |
| LLY | ~19% | ~16% | ~18% | ~22% | ~31.7% | ↑ Accelerating | GLP-1 manufacturing scale driving operating leverage |
| ASML | ~26% | ~29% | ~31% | ~27% | ~29.4% | ↑ Stable/High | Consistently ~27–31%; EUV monopoly pricing power |
| DY | ~3% | ~3.5% | ~4% | ~4.5% | ~5.1% | ↑ Improving | Low-margin contractor, but steadily expanding |
| ARGX | N/M | -36% | -16% | ~15% | ~31.1% | ↑ Hyperjump | Flipped to GAAP profitability in FY2024; massive improvement |
| DVN | ~16% | ~34% | ~23% | ~16% | ~13% | ↓ Cyclical | Tied to WTI oil prices |
| MDB | -37% | -56% | -28% | -15% | -8% | ↑ Improving | Still GAAP-negative but narrowing fast; Non-GAAP positive |
| GH | -109% | -146% | -85% | -59% | -42% | ↑ Improving | Pre-profitability; loss narrowing consistently |
| HQY | ~10% | ~12% | ~13% | ~16% | ~17% | ↑ Steady | Predictable margin expansion from custodial yield leverage |
| SBGSY | ~11.1% | ~10.2% | ~11.2% | ~11.2% | ~10.4% | → Stable | High-quality industrial; EBIT margin expanding |
| MRVL | ~6% | ~8% | ~5% | ~2.5% | ~36.2% | ↑ Surge | AI ASIC revenue transformed mix; massive margin expansion |
| JPM | ~29% | ~30% | ~31% | ~33% | ~31.2% | → Stable | Best-in-class bank ROTCE; NII drives net margin consistency |
| PH | ~10% | ~11% | ~10% | ~12% | ~13.5% | ↑ Improving | Meggitt integration + operating leverage; adj. margin ~23% |
| STLD | ~8% | ~15% | ~12% | ~10% | ~9% | ↓ Cyclical | EPS peaked FY2022 ($22.50); trough FY2025 ($7.99); recovering |
| WWD | ~8% | ~8.5% | ~9% | ~9.5% | ~10.1% | ↑ Improving | A&D mix shift to high-margin aftermarket content |
| MOG.A | ~6% | ~7% | ~7.5% | ~8% | ~8.5% | ↑ Improving | Sole-source defense pricing power; adj. EBITDA ~17% |
| ALNT | ~3% | ~3.2% | ~3.3% | ~2.5% | ~2.9% | → Flat | Acquisition integration costs suppressed; EPS recovery $1.32→$3.00E |
| ROR.L | ~17% | ~17.3% | ~17.5% | ~17% | ~14.8% | → Stable | Adj. op margin 24.6%; ROCE 25.8%; net cash £155M |
| ELF | ~3.5% | ~5.6% | ~10.6% | ~12.5% | ~8.5% | ↓ Compressed | FY22–FY24: rapid margin expansion (+5.6%→12.5%). FY25 dip from A&P investment. FY26 GAAP ~1.6% — depressed by ~$60–65M rhode intangible amortization + ~$50M interest expense. FCF $190M remains healthy. Adj. EBITDA margin ~9.8%. |
| Ticker | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|---|
| ABBV | $22,100M | $21,400M | $22,800M | $24,100M | ~$26,000M | ↑ FCF Machine |
| GOOGL | $67,012M | $60,010M | $69,495M | $72,764M | ~$73,300M | ↑ Massive & Growing |
| AVGO | ~$14,100M | ~$16,300M | ~$17,600M | ~$19,400M | ~$26,900M | ↑ Expanding |
| LLY | ~$5,800M | ~$5,300M | -$3,150M | ~$8,200M | ~$9,000M | ↑ (FY2023 capex dip) |
| ASML | €4,000M | €6,100M | €7,500M | €6,000M | ~€10,600M | ↑ Strong |
| DY | ~$180M | ~$250M | ~$310M | ~$360M | ~$402M | ↑ Steady Growth |
| ARGX | -€800M | -€900M | -€400M | ~€200M | ~€700M | ↑ Turned Positive |
| DVN | ~$1,800M | ~$4,600M | ~$3,800M | ~$2,900M | ~$2,100M | ↓ Cyclically Compressing |
| MDB | ~$25M | ~$100M | ~$260M | ~$420M | ~$500M | ↑ Compounding |
| GH | -$284M | -$387M | -$345M | -$275M | -$233M | ↑ Improving (still negative) |
| HQY | ~$200M | ~$280M | ~$350M | ~$410M | ~$455M | ↑ Steady Compounder |
| SBGSY | €2,700M | €3,300M | €4,500M | €4,600M | €4,900M | ↑ Best-in-class industrial FCF |
| MRVL | ~$900M | ~$1,500M | ~$1,700M | ~$1,600M | ~$3,200M | ↑ Surge (AI mix shift) |
| JPM | ~$48,300M | ~$37,700M | ~$49,600M | ~$58,500M | ~$54,000M | ↑ High & Growing (net income proxy) |
| PH | ~$1,200M | ~$1,400M | ~$1,800M | ~$2,500M | ~$3,340M | ↑ FCF Machine — 3-yr CAGR +33% |
| STLD | ~$700M | ~$2,100M | ~$1,200M | ~$800M | ~$502M | ↓ Cyclically compressed; Sinton capex peak |
| WWD | ~$180M | ~$200M | ~$225M | ~$250M | ~$285M | ↑ Steady compounder |
| MOG.A | ~$110M | ~$130M | ~$160M | ~$195M | ~$225M | ↑ Improving (defense cash flows) |
| ALNT | ~$18M | ~$20M | ~$22M | ~$15M | ~$28M | ↑ Small but recovering; leverage declining |
| ROR.L | ~£95M | ~£110M | ~£130M | ~£145M | ~£160M | ↑ Steady; net cash £155M (£M) |
| ELF | $14.7M | $100.2M | $62.5M | $115.3M | $190.1M | ↑ Strong (+65% YoY despite rhode integration) |
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Skyrizi (risankizumab) | ~$3.22B | +48% YoY | ~22% | IL-23 blockbuster; psoriasis + IBD expansion driving hypergrowth |
| Rinvoq (upadacitinib) | ~$1.49B | +60% YoY | ~10% | JAK inhibitor; multiple indications (RA, PsA, AD, IBD); rapidly scaling |
| HUMIRA (adalimumab) | ~$2.27B | −36% YoY | ~15% | Biosimilar erosion continuing; still material but declining ~30–40%/yr |
| Imbruvica (ibrutinib) | ~$1.09B | −12% YoY | ~7% | Blood cancer; share loss to zanubrutinib (BRUKINSA) |
| Venclexta (venetoclax) | ~$0.62B | +12% YoY | ~4% | BCL-2 inhibitor; AML + CLL steady grower |
| Aesthetics, Neuro & Other | ~$6.15B | +6% YoY | ~42% | Botox Cosmetic, Juvederm, Vraylar, eye care; diversified portfolio |
Q1 2026 total: ~$14.8B (+4% YoY). Skyrizi+Rinvoq combined: ~$4.7B, on track for $27B+ by FY2027. HUMIRA erosion more than offset by the immuno-oncology duo. Dividend: $6.56/share annualized (~3.6% yield). Net margin ~24%.
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| EUV Lithography (NXE/EXE systems) | ~€5.3B | +40%+ YoY | ~68% | High-NA EXE systems ramping; only source of cutting-edge EUV globally; monopoly pricing |
| DUV Lithography (TWINSCAN) | ~€1.7B | ~flat | ~22% | ArF immersion + KrF; mature nodes; China export controls limiting incremental growth |
| Service & Field Options (FSO) | ~€0.74B | +18% YoY | ~10% | Recurring high-margin revenue; grows as installed base expands |
Q1 2026 total: ~€7.74B. Gross margin ~54%. Order backlog: ~€36B (2+ yrs visibility). 100% Buy analyst consensus. EUV monopoly = most defensible moat in semiconductor equipment globally.
| Segment / Product | Most Recent Quarter | YoY | % Total | Commentary |
|---|---|---|---|---|
| AT&T (fiber + wireless) | ~$465M | +38% YoY | ~27% | BEAD + AT&T Fiber buildout; primary revenue driver; multi-year contracted |
| Lumen Technologies | ~$258M | +45% YoY | ~15% | Fiber-to-home + enterprise fiber; significant BEAD award wins |
| Comcast | ~$206M | +22% YoY | ~12% | HFC upgrades + DOCSIS 3.1→4.0 node splits |
| All Other Customers | ~$791M | +68% YoY | ~46% | Verizon, T-Mobile, Charter, utilities, federal BEAD awards |
Q1 FY27 total: $1.72B (+56% YoY). EPS $4.42 vs. est. $2.72 (+62% beat). Backlog: $11.9B. BEAD program ($42.5B federal broadband) = multi-year tailwind. 29th consecutive quarter of backlog growth.
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| VYVGART IV (efgartigimod) | ~€750M | +55% YoY | ~65% | gMG flagship; expanding into CIDP + ITP + PF; launched in 40+ countries |
| VYVGART Hytrulo (SC) | ~€340M | +85% YoY | ~29% | Subcutaneous co-formulation growing faster than IV; higher patient convenience |
| Collaboration & Other | ~€60M | +10% YoY | ~6% | AbbVie ARGX-117 collaboration; licensing fees |
Q1 2026 total: ~€1.15B (+58% YoY). Gross margin ~87%. GAAP net margin ~31%. CIDP approval = major new indication adding ~$2B+ TAM. argenx has the fastest-growing drug in immunology (VYVGART Hytrulo SC).
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Crude Oil | ~$1.78B | ~flat | ~65% | Delaware Basin core; ~275 MBoe/d; WTI pricing ~$70–75/bbl Q1 2026 |
| Natural Gas Liquids (NGL) | ~$380M | +8% YoY | ~14% | Permian NGLs; Mont Belvieu pricing |
| Natural Gas | ~$295M | −5% YoY | ~11% | Henry Hub pricing weakness persisting into 2026 |
| Other / Midstream | ~$285M | ~flat | ~10% | Gathering & processing; hedging gains |
Q1 2026 total: ~$2.74B. Production: ~725 MBoe/d. Variable dividend: fixed $0.22/qtr + variable tied to FCF. Net debt/EBITDA ~1.2x. PT of $62.75 implies +74% upside at current ~$36 price. HF Score 0.996 — near-perfect institutional conviction.
| Segment / Product | Most Recent Quarter | YoY | % Total | Commentary |
|---|---|---|---|---|
| Service Revenue | ~$163M | +14% YoY | ~47% | Account admin fees; grows with HSA account count (~9.5M accounts) |
| Custodial Revenue | ~$152M | +22% YoY | ~44% | Interest earned on $24B+ in HSA custodial assets; rate-sensitive but hedged |
| Interchange Revenue | ~$31M | +8% YoY | ~9% | Debit card transaction fees; grows with member spending activity |
Q1 FY27 total: ~$346M (+16% YoY). GAAP net margin ~17%. HSA assets: $24B+ growing ~18%/yr. The structural long-term compounder: every HSA account generates revenue for decades. Only stock in cohort with negative 1Y return (−12.5%) despite 91% Buy rate — classic contrarian setup. PT $121.50 (~40% upside).
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Energy Management | ~€5.9B | +12% YoY | ~61% | Electrical distribution, grid automation, UPS; AI data center buildout = major demand driver |
| Industrial Automation | ~€3.8B | +7% YoY | ~39% | SCADA, PLCs, drives; Aveva software; industrial IoT |
Q1 2026 total: ~€9.7B (+10% organic). Adj. EBITA margin ~20%+. Key megatrend exposure: AI data center power demand, grid modernization, energy transition. Exclusive supply agreements with major hyperscalers. Reports in EUR; SBGSY is US ADR.
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Consumer & Community Banking (CCB) | ~$18.6B | +6% YoY | ~40% | Retail banking + card services; ~86M consumer accounts; resilient NII |
| Corporate & Investment Bank (CIB) | ~$19.7B | +12% YoY | ~43% | Markets revenue surged; M&A advisory recovery; #1 global IB wallet share |
| Commercial Banking (CB) | ~$4.0B | +8% YoY | ~9% | Middle-market lending + treasury services; solid credit quality |
| Asset & Wealth Management (AWM) | ~$5.7B | +10% YoY | ~12% | AUM ~$4T; private banking growing fastest; fee income resilient |
| Corporate / Other | ~(−2.0B) | N/M | — | Treasury + equity investments; net drag on total |
Q1 2026 total revenue: ~$46.0B. Net income: ~$14.6B (ROTCE ~19%). CET1 ratio ~15.1% — fortress balance sheet. Dividend: $1.40/qtr ($5.60 annualized). Buybacks ongoing. Best-in-class large-cap bank.
| Segment / Product | Most Recent Quarter | YoY | % Total | Commentary |
|---|---|---|---|---|
| Aerospace Systems | ~$3.2B | +18% YoY | ~45% | Commercial OEM (Airbus, Boeing) + military aftermarket; backlog $15B+; highest-margin |
| Industrial — North America | ~$2.6B | +6% YoY | ~37% | Fluid power, motion & control; recovering from 2024 destocking; electrification tailwind |
| Industrial — International | ~$1.3B | +5% YoY | ~18% | Europe + APAC; semiconductor & energy markets strongest; FX headwind |
Q3 FY26 total: ~$7.1B. Adj. EBITDA margin ~25%+. FCF: ~$3.3B FY25 (consistent FCF machine). Meggitt acquisition (£6.3B, Sept 2022) now fully integrated and accretive. The premier diversified industrial compounder with decades of consistent margin expansion.
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Steel Operations | ~$3.05B | −8% YoY | ~78% | Flat-roll (Columbus Sinton + older mills) + long products; HRC price ~$850/ton Q1 2026 |
| Steel Fabrication (Vulcraft) | ~$490M | −5% YoY | ~13% | Joists, decking; non-res construction activity softening |
| Metals Recycling (OmniSource) | ~$350M | +3% YoY | ~9% | Scrap buying/selling; vertically integrated; offsets input cost volatility |
Q1 2026 total: ~$3.9B. EPS ~$1.95 GAAP (cyclical trough vs. peak $5.50 in 2022). Sinton Texas EAF mill (world's most efficient) now at 90%+ utilization — key margin recovery driver as HRC prices normalize. PT $275 implies meaningful upside on cycle recovery.
| Segment / Product | Most Recent Quarter | YoY | % Total | Commentary |
|---|---|---|---|---|
| Aerospace | ~$550M | +22% YoY | ~55% | Commercial OEM (CFM LEAP engines) + military actuation; Boeing/Airbus rate ramp; F-35 program |
| Industrial | ~$447M | +8% YoY | ~45% | Natural gas compression, power generation, marine; energy transition tailwind for gas turbine controls |
Q2 FY26 total: ~$997M. Adj. EBITDA margin ~22%. FCF ~$285M FY25. Woodward content on every CFM LEAP-1A/1B engine (A320neo / 737 MAX) = major production rate upside. 94% program-of-record sole-source content = predictable long-term revenue.
| Segment / Product | Most Recent Quarter | YoY | % Total | Commentary |
|---|---|---|---|---|
| Aircraft Controls | ~$548M | +14% YoY | ~55% | Fly-by-wire flight control actuators (F-35, A350, 787); 94% sole-source; strong aftermarket |
| Space & Defense Controls | ~$249M | +18% YoY | ~25% | Missiles, space launch vehicles, satellite attitude control; defense spending tailwind |
| Industrial Systems | ~$198M | +6% YoY | ~20% | Simulation, medical devices, test equipment; steady compounder |
Q2 FY26 total: ~$995M. Adj. EBITDA margin ~17%. FCF ~$225M FY25. Only 1 sell-side analyst covering (1B/0H/0S) — highly underfollowed small-cap defense play. 94% sole-source content on military programs = durable pricing power. Stock +110% 1Y.
| Segment / Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Defense & Space | ~$63M | +22% YoY | ~42% | HERO-certified motors for defense platforms; space actuators; DoD modernization tailwind |
| Medical | ~$34M | +18% YoY | ~23% | Surgical robots, imaging motors, drug delivery; high-value recurring platform revenue |
| Industrial / Automation | ~$31M | +8% YoY | ~21% | Factory automation motors + drives; recovering from 2024 destocking cycle |
| Aerospace / Other | ~$22M | +5% YoY | ~14% | Commercial aerospace, EV & energy storage, specialty markets |
Q1 2026 total: ~$150M. Revenue grew $305M→$554M (FY22→FY25) via acquisitions. Adj. EBITDA margin ~18%. Net Debt/EBITDA declining toward 1.0x. Internal PT $85 vs. consensus $73.80. SS 10 despite small cap (~$1.2B mkt cap).
| Segment / Product | FY2025 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Oil & Gas | £265M | +5% YoY | ~34% | LNG, upstream production, pipeline; Middle East and energy security spending |
| Water & Power | £313M | +4% YoY | ~40% | Water utilities (ESG regulation) + power generation; recurring maintenance revenue |
| Industrial & Commercial | £199M | +3% YoY | ~26% | Pharmaceuticals, food & bev, mining; diversified non-cyclical end markets |
FY2025 total: £777M (+3% organic). Adj. operating margin 24.6%. ROCE 25.8%. Net cash £155M. FCF ~£160M. Makes electric, pneumatic, and hydraulic actuators for valves in process industries — irreplaceable with 50%+ gross margins. Listed on LSE (ROR.L). Reports in GBp.
| Segment | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Google Search & Other | ~$54B | +12% | ~54% | Resilient core; AI Overviews enhancing query monetization |
| Google Cloud | ~$12.3B | +28% | ~12% | Fastest-growing segment; AI workloads accelerating |
| YouTube Ads | ~$8.9B | +10% | ~9% | Shorts monetization improving |
| Google Network | ~$7.3B | -3% | ~7% | Secular decline |
| Other Bets & Services | ~$17.4B | +9% | ~17% | Google One, Pixel, Waymo milestones |
| Segment | Q1 FY26 | YoY | % Total | Commentary |
|---|---|---|---|---|
| AI Semiconductors | ~$4.1B | +77% | ~26% | XPUs for hyperscaler AI clusters; Google TPU, Meta MTIA |
| Infrastructure Software (VMware) | ~$6.7B | +47% | ~42% | VMware integration ahead of plan |
| Networking (Non-AI) | ~$3.2B | +8% | ~20% | Enterprise networking recovery |
| Storage / Other | ~$1.9B | -5% | ~12% | Legacy storage declining |
| Product | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Mounjaro (tirzepatide) — T2D | ~$3.8B | +65% | ~26% | Core GLP-1 product; international expanding |
| Zepbound (tirzepatide) — Obesity | ~$2.6B | New | ~18% | Fastest new drug launch in pharma history |
| Verzenio (abemaciclib) | ~$1.2B | +18% | ~8% | Breast cancer CDK4/6 inhibitor; growing market share |
| Taltz / Jardiance / Other | ~$6.9B | +6% | ~47% | Diversified portfolio; steady contributors |
| Segment | Q1 FY26 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Atlas (Cloud / Multi-Cloud) | ~$375M | +35% | ~72% | Primary growth driver; AI workloads lifting consumption |
| Enterprise Advanced (on-prem) | ~$145M | -5% | ~28% | Legacy perpetual licenses declining; migrating to Atlas |
| Segment | Q1 2026 | YoY | % Total | Commentary |
|---|---|---|---|---|
| Oncology (G360 + Reveal) | $205.0M | +36% | 68% | Core franchise; ~86K tests (+47% volume YoY) |
| Screening (Shield) | $41.6M | +600%+ | 14% | FDA-approved July 2024; accelerating with every new payer coverage win |
| Biopharma & Data | $53.0M | +17% | 18% | Pharma clinical trial testing + data licensing |
Q1 2026 total: $301.7M (+48.3% YoY). GH raised FY2026 guidance to $1.30–$1.32B.
| Segment | Q1 FY26 | YoY | % Total | Commentary |
|---|---|---|---|---|
| AI / Data Center | ~$1.7B | +90%+ | ~62% | Custom AI ASICs + 800G PAM4 DSPs; structural shift |
| Carrier / Enterprise Networking | ~$580M | +12% | ~21% | Recovering from cyclical downturn |
| Storage / Other | ~$460M | -8% | ~17% | Legacy declining; MRVL de-emphasizing non-AI hardware |
| Brand / Segment | FY2026 Net Sales | YoY | % Total | Commentary |
|---|---|---|---|---|
| rhode skin | $390M | +80%+ | ~24% | #1 brand at Sephora N. America; Sephora Europe (19 countries) Sep 2026 |
| e.l.f. Cosmetics (core) | ~$1,100M | +7% | ~67% | #1 U.S. mass color cosmetics; 29 consecutive growth quarters; 13–20 wk speed-to-market |
| e.l.f. SKIN + Naturium | ~$146M | +12% | ~9% | SKIN rose from #25→#11 in U.S. mass skincare; Naturium premium positioning |
FY2026 total net sales: $1.636B (+24.5% YoY). FY2027 guidance: $1.84–$1.87B (+12–14%). Gross margin: 70.7%. FCF: $190M. Tariff exposure: ~75% China manufacturing; $50M annualized impact at current 55% tariff rate. Source: SEC EDGAR 10-K (filed 2026-05-21).
| Ticker | Growth | Quality/Moat | Profitability | Analyst Sent. | Technicals | Valuation | TAM/Position | OVERALL | Verdict |
|---|---|---|---|---|---|---|---|---|---|
| ABBV | 7.5 | 9.0 | 9.5 | 8.5 | 8.0 | 8.0 | 8.5 | ~8.5 | Top compounder; Skyrizi/Rinvoq transition ahead of schedule. Dividend + buyback fortress. |
| GOOGL | 8.5 | 9.5 | 9.5 | 9.0 | 8.0 | 8.5 | 9.0 | 8.4 | AI re-rating in progress. Cloud + Gemini. FCF $73B. Reasonable 28.7× for compounding quality. |
| AVGO | 9.0 | 9.0 | 9.0 | 9.0 | 8.0 | 7.5 | 9.0 | 8.6 | AI ASIC + VMware = premium franchise. Best-in-class FCF per share growth. |
| LLY | 9.5 | 9.0 | 8.5 | 9.0 | 7.5 | 7.0 | 9.5 | 8.3 | GLP-1 mega-cycle. Obesity + T2D TAM = multi-trillion. Capex buildout nearing completion. |
| ASML | 9.0 | 10.0 | 9.0 | 10.0 | 8.0 | 7.5 | 9.5 | 8.6 | Irreplaceable EUV monopoly. Generational moat. Every advanced chip made anywhere uses ASML. |
| DY | 8.5 | 7.5 | 7.0 | 9.5 | 7.0 | 6.5 | 7.5 | 7.4 | BEAD/fiber play. Q1 FY2027: +56% Rev, EPS $4.42 vs $2.72 est. Backlog $11.9B. |
| ARGX | 9.5 | 8.5 | 8.0 | 9.0 | 7.5 | 7.0 | 8.5 | 8.0 | VYVGART commercial explosion. Flipped to GAAP profitability. Pipeline loaded. |
| DVN | 5.0 | 7.0 | 7.5 | 8.5 | 5.0 | 8.5 | 6.0 | 7.0 | Cheapest (P/E 12.2×). Highest HF Score (0.996). Commodity risk remains. |
| MDB | 9.0 | 8.5 | 7.0 | 9.0 | 7.5 | 7.0 | 8.5 | 8.1 | Atlas 72% of revenue. Developer-first flywheel. FCF $500M+. AI vector search = new catalyst. |
| GH | 9.5 | 8.0 | 7.0 | 9.0 | 6.5 | 6.0 | 9.0 | 7.9 | +219% 1Y. Shield FDA-approved, ramp underway. Our PT: $160 BUY. View Full Report → |
| HQY | 7.5 | 8.0 | 8.0 | 8.0 | 6.5 | 8.5 | 7.5 | 7.6 | Only negative 1Y return. Contrarian setup — 91% Buy rate, ~40% upside to PT. |
| SBGSY | 8.0 | 9.0 | 8.5 | 8.5 | 8.0 | 7.0 | 9.0 | 8.2 | Pure-play electrification and automation. High-quality European industrial compounder. |
| MRVL | 9.5 | 8.5 | 7.0 | 9.0 | 8.0 | 6.5 | 9.0 | 7.9 | Best 1Y performer (+240.6%). AI ASIC 62% of revenue. Non-GAAP PE ~36× more reasonable. |
| JPM | 6.5 | 9.5 | 9.0 | 7.0 | 7.5 | 7.5 | 8.5 | 7.5 | World's most profitable bank. 21% ROTCE vs peer avg 12–15%. $55B+ excess capital. PT $335 BUY. |
| PH | 7.5 | 9.5 | 9.5 | 8.5 | 8.0 | 7.5 | 9.0 | 8.5 | Premier motion & control compounder. $3.3B FCF. Meggitt integration ahead of schedule. PT $1,000. |
| STLD | 6.5 | 8.0 | 7.5 | 8.0 | 7.5 | 8.5 | 7.5 | 7.6 | Section 232 tariff floor + Sinton EAF ramp. Steel cycle recovery underway. PT $275 BUY. |
| WWD | 7.5 | 8.5 | 8.0 | 8.5 | 7.5 | 7.0 | 8.0 | 7.9 | Dual-cycle A&D + energy platform. Sole-source content. Low HF Score (0.04) = contrarian signal. PT $420. |
| MOG.A | 7.5 | 9.0 | 8.0 | 7.0 | 7.0 | 7.5 | 8.5 | 7.8 | 94% sole-source defense. Only 1 analyst — underfollowed gem. Stock above consensus PT. Int. PT $370. |
| ALNT | 9.0 | 7.5 | 7.0 | 8.5 | 7.5 | 7.0 | 8.0 | 7.8 | +160% 1Y return. 127% EPS recovery CAGR. Net Debt/EBITDA 3.3×→1.0×. Above consensus PT. Int. PT $85. |
| ROR.L | 7.5 | 9.0 | 8.5 | 8.0 | 7.5 | 8.0 | 8.5 | 8.1 | Pricing power moat. ROCE 25.8%. Net cash. Global flow control platform. 65% buy-rate. PT 390p. |
| ELF | 8.0 | 8.0 | 6.5 | 8.5 | 3.0 | 8.5 | 8.0 | 7.2 | Contrarian setup: −53% 1Y, 43% PT upside. rhode brand growing 80%+ YoY. FCF $190M. Tariff risk + technicals drag score. |
| 1. | AVGO | 8.6/10 |
| 1. | ASML | 8.6/10 |
| 3. | ABBV | ~8.5/10 |
| 4. | GOOGL | 8.4/10 |
| 5. | LLY | 8.3/10 |
| 1. | MRVL | +240.6% |
| 2. | GH | +219.3% |
| 3. | DY | +121.8% |
| 4. | GOOGL | +121.3% |
| 5. | ASML | +115.9% |
| 1. | DVN | P/E 12.2×, HF 0.996 |
| 2. | HQY | ~40% PT upside |
| 3. | ABBV | Dividend yield + buyback |
| 4. | GOOGL | 28.7× for quality |
| 4. | ELF | 43% PT upside, −53% 1Y |
| 5. | MDB | ~40% PT upside |